Dmitry Balyasny’s Regenxbio RGNX Stock Holding History

Dmitry Balyasny’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-144,000	Closed	-$2.37M	–	2832
2023 Q3	$2.37M	Buy	144,000 +91,000	+172%	+$1.65M	﹤0.01%	1333
2023 Q2	$1.06M	Buy	+53,000	New	+$1.02M	﹤0.01%	1598
2019 Q1	–	Sell	-115,800	Closed	-$4.86M	–	1609
2018 Q4	$4.86M	Buy	+115,800	New	+$6.79M	0.04%	511

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dmitry Balyasny's RGNX Position: Q2 2026 in Review

Dmitry Balyasny increased its Regenxbio (RGNX) stake by 535% in Q2 2026, buying an estimated $518K and bringing the position to 74,047 shares worth $887K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Dmitry Balyasny first reported a position in RGNX in Q1 2018 and has held it in 19 quarters since. The position peaked at $13M in Q3 2023. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Dmitry Balyasny held 74,047 shares of Regenxbio worth $887K as of Q2 2026.
Dmitry Balyasny bought 62,391 Regenxbio shares in Q2 2026, an estimated $518K.
Regenxbio made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2278 holding.
Dmitry Balyasny first reported a position in Regenxbio in Q1 2018 and has held it in 19 quarters since.
Dmitry Balyasny's Regenxbio position peaked at $13M in Q3 2023.
164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.